EUVIMEDOdkrijte EUVIMED
Crossref

Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's Disease

A W Teelken, G A van den Berg, F A Muskiet, A L Staal-Schreinemachers, B G Wolthers, J P Lakke

Journal of Neural Transmission - Parkinson's Disease and Dementia Section · 1989

DOI: 10.1007/bf02248667 ↗

At a glance

Journal article in Journal of Neural Transmission - Parkinson's Disease and Dementia Section, 1989. Written by A W Teelken and 5 co-authors. Institution: Department of Neurology, University Hospital, Groningen, The Netherlands. Cited 5 times so far (Crossref); 36 references.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

DL-threo-3,4-dihydroxyphenylserine (DL-threo-DOPS) was administered during 10 days to 4 patients with longstanding Parkinson's disease in addition to their treatment with L-3,4-dihydroxyphenyl-L-alanine (L-DOPA)-carbidopa (Sinemet). All patients tended to improve in their symptoms freezing, all day life activity and mood. There were no improvements in rigidity, tremor, and akinesia (in general). During the DL-threo-DOPS-treatment cerebrospinal fluid (CSF), serum and urine concentrations of catecholamines were measured. The results show that DL-threo-DOPS is transported to the brain and CSF in a way comparable with L-DOPA. However, no measurable increase of 3-methoxy-4-hydroxyphenylethyleneglycol (MOPEG) in CSF could be demonstrated. This suggests that the synthesis of noradrenaline from DL-threo-DOPS in the brain is doubtful. In addition measurements in urine reveals that at the dose used Sinemet prevents peripheral decarboxylation of DL-threo-DOPS into noradrenaline. Other possible metabolic pathways of DL-threo-DOPS are discussed.

Subjects

MeSH terms (MEDLINE)

3,4-Dihydroxyphenylacetic AcidAgedCatecholaminesDopamineDroxidopaFemaleHomovanillic AcidHumansHydroxyindoleacetic AcidMaleMiddle AgedParkinson Disease, SecondarySerine

Substances

Catecholamines3,4-Dihydroxyphenylacetic AcidSerineHydroxyindoleacetic AcidDroxidopaDopamineHomovanillic Acid

Authors and institutions

  • Department of Neurology, University Hospital, Groningen, The Netherlands.

Cite

APA

Teelken, A. W., van den Berg, G. A., Muskiet, F. A., Staal-Schreinemachers, A. L., Wolthers, B. G., & Lakke, J. P. (1989). Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's Disease. Journal of Neural Transmission - Parkinson's Disease and Dementia Section. https://doi.org/10.1007/bf02248667

Vancouver

Teelken AW, van den Berg GA, Muskiet FA, Staal-Schreinemachers AL, Wolthers BG, Lakke JP. Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's Disease. Journal of Neural Transmission - Parkinson's Disease and Dementia Section. 1989. doi:10.1007/bf02248667

BibTeX
@article{Teelken1989,
  author = {Teelken, A W and van den Berg, G A and Muskiet, F A and Staal-Schreinemachers, A L and Wolthers, B G and Lakke, J P},
  title = {Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's Disease},
  journal = {Journal of Neural Transmission - Parkinson's Disease and Dementia Section},
  year = {1989},
  doi = {10.1007/bf02248667}
}
Start for free →